Rett Syndrome Clinical Trial
Official title:
Open-label, Randomized, Dose-escalation and Dose-expansion Study of the Safety and Preliminary Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, in the Treatment of Adult Females With Rett Syndrome
The REVEAL Adult Study is a multi-center, Phase 1/2 open-label, dose-escalation study of TSHA-102, an investigational gene therapy, in adult females with Rett syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study duration is estimated to be up to 63 months.
Status | Recruiting |
Enrollment | 18 |
Est. completion date | January 5, 2032 |
Est. primary completion date | November 8, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - Participant has a clinical diagnosis of classical/typical Rett syndrome with a documented pathogenic mutation of the methyl-CpG-binding protein 2 (MECP2) gene that results in loss of function. - Participants must be willing to receive blood or blood products for the treatment of an AE if medically needed. Exclusion Criteria: - Participant has another neurodevelopmental disorder independent of the MECP2 loss-of-function mutation, or any other genetic syndrome with a progressive course. - Participant has a history of brain injury that causes neurological problems. - Participant had grossly abnormal psychomotor development in the first 6 months of life. - Participant has a diagnosis of atypical Rett syndrome. - Participant has a MECP2 mutation that does not cause Rett syndrome. - Participant requires invasive ventilatory support. - Participant has contraindications for IT administration of TSHA-102 or lumbar puncture procedure, or other medical conditions, or contraindications to any medications required for IT administration. - Participant has uncontrolled seizures or a history of status epilepticus within the 3 months prior to enrollment. |
Country | Name | City | State |
---|---|---|---|
Canada | Taysha Study Site | Montréal | |
United States | Rush University Medical Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Taysha Gene Therapies, Inc. |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportions of participants experiencing any treatment-emergent adverse events (AEs) and serious adverse events (SAEs) | Baseline through Week 52 | ||
Primary | Change from baseline in participant's status after TSHA-102 administration as assessed by Clinical Global Impressions-Improvement (CGI-I) scale, adapted to Rett syndrome | Baseline through Week 52 | ||
Primary | Change from baseline in participant's status after TSHA-102 administration as assessed by the Revised Motor Behavior Assessment (R-MBA) | Baseline through Week 52 | ||
Primary | Change from baseline in participant's status after TSHA-102 administration as assessed by the Rett Syndrome Hand Function Scale (RSHFS) | Baseline through Week 52 | ||
Secondary | Change from Baseline in participant's status after TSHA-102 administration as assessed by Clinical Global Impressions-Severity (CGI-S) | Baseline through Week 52 | ||
Secondary | Change from baseline in monthly seizure frequency (52 weeks) | Baseline through Week 52 | ||
Secondary | Change from baseline in adaptive behavior as assessed by Vineland-3 | Baseline through Week 52 | ||
Secondary | Change from Baseline in quantitative EEG findings with visual evoked potentials | Baseline through Week 52 | ||
Secondary | Change from Baseline in quantitative EEG findings with auditory evoked potentials | Baseline through Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04988867 -
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT00069550 -
Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome
|
Phase 3 | |
Enrolling by invitation |
NCT06139172 -
Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities
|
N/A | |
Not yet recruiting |
NCT04014985 -
Patients With RETT Syndrome
|
N/A | |
Not yet recruiting |
NCT04041713 -
A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome
|
Phase 2 | |
Completed |
NCT02705677 -
Biobanking of Rett Syndrome and Related Disorders
|
||
Terminated |
NCT02790034 -
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
|
Phase 2/Phase 3 | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT05932589 -
Neurophysiologic Biomarkers in Rett Syndrome
|
||
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Completed |
NCT04776746 -
Open-Label Extension Study of Trofinetide for Rett Syndrome
|
Phase 3 | |
Completed |
NCT04181723 -
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDERâ„¢)
|
Phase 3 | |
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT04514549 -
ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME
|
||
Completed |
NCT02738281 -
Natural History of Rett Syndrome & Related Disorders
|
||
Terminated |
NCT02562820 -
An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome
|
Phase 1 | |
Completed |
NCT05687214 -
Osteopathic Manipulative Treatment for Constipation in People With Rett Syndrome
|
N/A | |
Recruiting |
NCT06199700 -
Esketamine for the Treatment of Rett Syndrome
|
Early Phase 1 | |
Completed |
NCT03941444 -
ANAVEX2-73 Study in Patients With Rett Syndrome
|
Phase 3 | |
Recruiting |
NCT06346106 -
The Diagnostic Experience of Male Rett Syndrome
|